Human LBP

HK315

Edition 10-16

ELISA KIT
PRODUCT INFORMATION & MANUAL

Read carefully prior to starting procedures!
For use in laboratory research only
Not for clinical or diagnostic use



FOR REFERENCE USE ONLY

info@hycultbiotech.com ● www.hycultbiotech.com

Note that this user protocol is not lot-specific and is representative for the current specifications of this product. Please consult the vial label and the Certificate of Analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.

FOR REFERENCE USE ONLY

TABLE OF CONTENTS

Page

1. Intended use 2
2. Introduction 2
3. Kit features 2
4. Protocol overview 3
5. Kit components and storage instructions 4
6. Warnings and precautions 5
7. Sample preparation 5
8. Reagent preparation 7
9. ELISA protocol 8
10. Interpretation of results 9
11. Technical hints 9
12. Quality control 10
13. Performance characteristics 10
14. Troubleshooting 11
15. References 12

FOR REFERENCE USE ONLY

1. INTENDED USE

The human LBP ELISA kit is to be used for the *in vitro* quantitative determination of human LBP in serum, plasma and cell culture supernatant samples. This kit is intended for laboratory research use only and is not for use in diagnostic or therapeutic procedures.

The analysis should be performed by trained laboratory professionals.

2. INTRODUCTION

Lipopolysaccharide (LPS) Binding Protein (LBP) is a type 1 acute phase protein that is constitutively produced by the liver and rapidly upregulated during the acute phase response. LBP plays a central role in the response to LPS. The protein catalyzes the monomerization of LPS and its transfer to (s)CD14 and to lipoproteins. This way LBP has both a role in the activation pathway of LPS: activation of monocytes by LPS leading to release of inflammatory mediators and in the neutralization of LPS i.e. the uptake of LPS by lipoprotein and subsequent clearing.

In plasma of healthy individuals LBP is present at levels of approximately 10 µg/ml, which increase approximately 10-fold during acute phase responses.

3. KIT FEATURES

- Working time of 3½ hours.
- Minimum concentration which can be measured is 4.4 ng/ml.
- Measurable concentration range of 4.4 to 50 ng/ml.
- Working volume of 100 µl/well.

Cross-reactivity

Potential cross-reacting proteins detected in the human LBP ELISA:


Cross reactant	Reactivity
Bovine LBP	Negative
Dog LBP	Negative
Goat LBP	Negative
Horse LBP	Negative
Mouse LBP	Negative
Rabbit LBP	Negative
Rat LBP	Negative
Pig LBP	Negative
Sheep LBP	Negative

Table 1

Cross-reactivity for other species or proteins/peptides has not been tested.

FOR REFERENCE USE ONLY

4. PROTOCOL OVERVIEW



- The human LBP ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 3½ hours.
- The efficient format of a plate with twelve disposable 8-well strips allows free choice of batch size for the assay.
- Samples and standards are incubated in microtiter wells coated with antibodies recognizing human LBP.
- Biotinylated tracer antibody will bind to captured human LBP.
- Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody.
- Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB).
- The enzyme reaction is stopped by the addition of oxalic acid.
- The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human LBP standards (log).
- The human LBP concentration of samples, which are run concurrently with the standards, can be determined from the standard curve.

FOR REFERENCE USE ONLY

5. KIT COMPONENTS AND STORAGE INSTRUCTIONS

Kit component	Cat. #	Quantity HK315-01	Quantity HK315-02	Color code
Wash/dilution buffer A 20x	WBDB51	1 vial (60 ml)	1 vial (60 ml)	Colorless
Wash/dilution buffer B 40x	WBDB31	1 vial (30 ml)	1 vial (30 ml)	Colorless
Standard		2 vials, lyophilized	4 vials, lyophilized	White
Tracer, biotinylated		1 vial, 1 ml lyophilized	2 vials, 1 ml lyophilized	White
Streptavidin-peroxidase 100x	CON03	1 tube, 0.25 ml in solution	1 tube, 0.25 ml in solution	Brown
TMB substrate	TMB050/TMB100	1 vial (11 ml)	1 vial (22 ml)	Brown
Stop solution	STOP110	1 vial (22 ml)	1 vial (22 ml)	Red
12 Microtiter strips, pre-coated		1 plate	2 plates	
Certificate of Analysis		1	1	
Manual		1	1	
Data collection sheet		2	2	

Table 2

- Upon receipt, store individual components at 2 - 8°C. Do not freeze.
- Do not use components beyond the expiration date printed on the kit label.
- The standard and tracer in lyophilized form and the streptavidin-peroxidase in concentrated solution are stable until the expiration date indicated on the kit label, if stored at 2 - 8°C.
- The exact amount of the standard is indicated on the label of the vial and the Certificate of Analysis.
- The standard is single use. After reconstitution the standard must be used within 1 hour. The standard cannot be stored for repeated use.
- Once reconstituted the tracer is stable for 1 month if stored at 2 - 8°C.
- The streptavidin-peroxidase can only be stored in concentrated solution and is not stable when stored diluted.
- Upon receipt, foil pouch around the plate should be vacuum-sealed and unpunctured. Any irregularities to aforementioned conditions may influence plate performance in the assay.
- Return unused strips immediately to the foil pouch containing the desiccant pack and reseal along the entire edge of the zip-seal. Quality guaranteed for 1 month if stored at 2 - 8°C.

Materials required but not provided

- Calibrated micropipettes and disposable tips.
- Distilled or de-ionized water.
- Plate washer: automatic or manual.
- Polypropylene tubes.
- Calibrated ELISA plate reader capable of measuring absorbance at 450 nm.
- Adhesive covers can be ordered separately. Please contact your local distributor.
- Centrifuge for 1 ml tubes.

FOR REFERENCE USE ONLY

6. WARNINGS AND PRECAUTIONS

- For research use only, not for diagnostic or therapeutic use.
- This kit should only be used by qualified laboratory staff.
- Do not add under any circumstances sodium azide as preservative to any of the components.
- Do not use kit components beyond the expiration date.
- Do not mix reagents from different kits and lots. The reagents have been standardized as a unit for a given lot. Use only the reagents supplied by manufacturer.
- The assay has been optimized for the indicated standard range. Do not change the standard range.
- Open vials carefully: vials are under vacuum.
- It is advised to spin down streptavidin-peroxidase tubes before use.
- Do not ingest any of the kit components.
- Kit reagents contain 2-chloroacetamide as a preservative. 2-Chloroacetamide is harmful in contact with skin and toxic if swallowed. In case of accident or if you feel unwell, seek medical advice immediately.
- The TMB substrate is light sensitive, keep away from bright light. The solution should be colorless until use.
- The stop solution contains 2% oxalic acid and can cause irritation or burns to respiratory system, skin and eyes. Direct contact with skin and eyes should be strictly avoided. If contact occurs, rinse immediately with plenty of water and seek medical advice.
- Incubation times, incubation temperature and pipetting volumes other than those specified may give erroneous results.
- Do not reuse micro wells or pour reagents back into their bottles once dispensed.
- Handle all biological samples as potentially hazardous and capable of transmitting diseases.
- Hemolyzed, hyperlipemic, heat-treated or contaminated samples may give erroneous results.
- Use polypropylene tubes for preparation of standard and samples. Do not use polystyrene tubes or sample plates.
- The standard is of human origin. It was tested for various viruses and found negative. Since no test method can offer complete assurance that infectious agents are absent, this reagent should be handled as any potentially infectious human serum or blood specimen. Handle all materials in contact with this reagent according to guide-lines for prevention of transmission of blood-borne infections.

7. SAMPLE PREPARATION

Collection and handling

Serum or plasma

Collect blood using normal aseptic techniques. Blood samples should be kept on ice. Most reliable results are obtained if EDTA plasma is used. If serum is used, separate serum from blood after clotting at room temperature within 1 hour by centrifugation (1,500xg at 4°C for 15 min). Transfer the serum to a fresh polypropylene tube.

If plasma is used, separate plasma from blood within 20 minutes after blood sampling by centrifugation (1,500xg at 4°C for 15 min). Transfer the plasma to a fresh polypropylene tube.

FOR REFERENCE USE ONLY

Storage

Store samples below -20°C, preferably at -70°C in polypropylene tubes. Storage at -20°C can affect recovery of human LBP. Use samples within 24 hours after thawing. Avoid multiple freeze-thaw cycles which may cause loss of human LBP activity and give erroneous results.

Do not use hemolyzed, hyperlipemic, heat-treated or contaminated samples.

Before performing the assay, samples should be brought to room temperature (18 – 25°C) and mixed gently. Prepare all samples (controls and test samples) prior to starting the assay procedure. Avoid foaming.

Dilution procedures

Serum or plasma samples

Human LBP can be measured accurately if serum or plasma samples are diluted at least 1,000x with supplied wash/dilution buffer in polypropylene tubes.

Note that most reliable results are obtained with EDTA plasma.

Remark regarding recommended sample dilution

The mentioned dilution for samples is a minimum dilution and should be used as a guideline. The recovery of human LBP from an undiluted sample is not 100% and may vary from sample to sample. When testing less diluted samples it is advisable to run recovery experiments to determine the influence of the matrix on the detection of human LBP.

Do not use polystyrene tubes or sample plates for preparation or dilution of the samples.

Guideline for dilution of samples

Please see the table below for recommended sample dilutions. Volumes are based on a total volume of at least 230 µl of diluted sample, which is sufficient for one sample in duplicate in the ELISA. For dilution of samples we recommend to use at least 10 µl of sample.

	Dilution	Pre-dilution	Amount of sample or pre-dilution required	Amount of Wash/Dilution buffer required
1.	10x	Not necessary	25 µl (sample)	225 µl
2.	20x	Not necessary	15 µl (sample)	285 µl
3.	50x	Not necessary	10 µl (sample)	490 µl
4.	100x	Not necessary	10 µl (sample)	990 µl
5.	500x	Recommended: 10x (see nr.1)	10 µl (pre-dilution)	490 µl
6.	1,000x	Recommended: 10x (see nr.1)	10 µl (pre-dilution)	990 µl
7.	2,000x	Recommended: 20x (see nr.2)	10 µl (pre-dilution)	990 µl
8.	5,000x	Recommended: 50x (see nr.3)	10 µl (pre-dilution)	990 µl

Table 3

FOR REFERENCE USE ONLY

8. REAGENT PREPARATION

Allow all the reagents to equilibrate to room temperature (20 – 25°C) prior to use. Return to proper storage conditions immediately after use.

Wash/dilution buffer

Dilute 20x concentrated wash/dilution buffer A by mixing 60 ml with 540 ml distilled or de-ionized water. Dilute 40x concentrated wash/dilution buffer B by mixing 30 ml with 570 ml distilled or de-ionized water. Finally combine both solutions equally and mix well. The wash/dilution buffer is sufficient for 2 x 96 tests.

In case less tests are required, prepare the required volume by dilution of 1 part 20x concentrated wash/dilution buffer A with 9 parts of distilled or de-ionized water and 1 part 40x concentrated wash/dilution buffer B with 19 parts of distilled or de-ionized water. Finally combine both solutions equally and mix well.

Concentrated wash/dilution buffer may contain crystals. In case crystals do not disappear at room temperature within 1 hour, concentrated wash/dilution buffer can be warmed up to 37°C. Do not shake.

Standard solution

The standard is reconstituted by pipetting the amount of wash/dilution buffer mentioned on the CoA in the standard vial. Use the standard vial as Tube 1 in Figure 1. Prepare each human LBP standard in polypropylene tubes by serial dilution of the reconstituted standard with wash/dilution buffer as shown in Figure 1*. After reconstitution the standard must be used within 1 hour and the standard cannot be stored for repeated use.




Figure 1

*) CoA: Certificate of Analysis, Rec. St: Reconstituted Standard, W/Db: Wash/dilution buffer

Tracer solution

The tracer is reconstituted by pipetting 1 ml distilled or de-ionized water. Dilute the reconstituted 1 ml tracer with 11 ml wash/dilution buffer, which is sufficient for 1 x 96 tests. In case less volume is required, prepare the desired volume of tracer by diluting 1 part of the reconstituted tracer with 11 parts of wash/dilution buffer.

Streptavidin-peroxidase solution

It is advised to spin down streptavidin-peroxidase tubes before use. Prepare the streptavidin-peroxidase solution by mixing 0.25 ml of the 100x streptavidin-peroxidase solution with 24.75 ml wash/dilution buffer, which is sufficient for 2 x 96 tests. In case less volume is required, prepare the desired volume of streptavidin-peroxidase solution by diluting 1 part of the 100x streptavidin-peroxidase solution with 99 parts of wash/dilution buffer.

FOR REFERENCE USE ONLY

9. ELISA PROTOCOL

Bring all reagents to room temperature (20 - 25°C) before use.

1. Determine the number of test wells required, put the necessary microwell strips into the supplied frame, and fill out the data collection sheet. Return the unused strips to the storage bag with desiccant, seal and store at 2 - 8°C.
2. Wash the plates 4 times with wash/dilution buffer using a plate washer or as follows*:
   a. Carefully remove cover, avoid splashing.
   b. Empty the plate by inverting plate and shaking contents out over the sink, keep inverted and tap dry on a thick layer of tissues.
   c. Add 200 µl of wash/dilution buffer to each well, wait 20 seconds, empty the plate as described in 2b.
   d. Repeat the washing procedure 2b/2c three times.
   e. Empty the plate and gently tap on thick layer of tissues.
3. Transfer 100 µl in duplicate of standard, samples, or controls into appropriate wells. Do not touch the side or bottom of the wells.
4. Cover the tray and tap the tray to eliminate any air bubbles. Be careful not to splash liquid onto the cover.
5. Incubate the strips or plate for 1 hour at room temperature.
6. Repeat the wash procedure described in step 2.
7. Add 100 µl of diluted tracer to each well using the same pipetting order as applied in step 2. Do not touch the side or bottom of the wells.
8. Cover the tray and incubate the tray for 1 hour at room temperature.
9. Repeat the wash procedure described in step 2.
10. Add 100 µl of diluted streptavidin-peroxidase to each well, using the same pipetting order as applied in step 3. Do not touch the side or bottom of the wells.
11. Cover the tray and incubate the tray for 1 hour at room temperature.
12. Repeat the wash procedure described in step 2.
13. Add 100 µl of TMB substrate to each well, using the same pipetting order as applied in step 3. Do not touch the side or bottom of the wells.
14. Cover the tray and incubate the tray for 30 minutes at room temperature. It is advised to control the reaction on the plate regularly. In case of strong development the TMB reaction can be stopped sooner. Avoid exposing the micro well strips to direct sunlight. Covering the plate with aluminium foil is recommended.
15. Stop the reaction by adding 100 µl of stop solution with the same sequence and timing as used in step 13. Mix solutions in the wells thoroughly by gently swirling the plate. Gently tap the tray to eliminate any air bubbles trapped in the wells.
16. Read the plate within 30 minutes after addition of stop solution at 450 nm using a plate reader, following the instructions provided by the instrument's manufacturer.

*) In case plate washer is used, please note: use of a plate washer can result in higher background and ` decrease in sensitivity. We advise validation of the plate washer with the manual procedure.
Make sure the plate washer is used as specified for the manual method.

FOR RESEARCH USE ONLY

10. INTERPRETATION OF RESULTS

- Calculate the mean absorbance for each set of duplicate standards, control and samples.
- If individual absorbance values differ by more than 15% from the corresponding mean value, the result is considered suspect and the sample should be retested.
- The mean absorbance of the zero standard should be less than 0.3.
- Create a standard curve using computer software capable of generating a good curve fit. The mean absorbance for each standard concentration is plotted on the vertical (Y) axis versus the corresponding concentration on the horizontal (X) axis (logarithmic scale).
- If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.
- Samples that give a mean absorbance above the absorbance for the highest standard concentration are out of range of the assay. These samples should be retested at a higher dilution.

11. TECHNICAL HINTS

- User should be trained and familiar with ELISA assays and test procedure.
- If you are not familiar with the ELISA technique it is recommended to perform a pilot assay prior to evaluation of your samples. Perform the assay with a standard curve only following the instructions.
- Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Completely empty wells before dispensing wash buffer, fill with wash buffer as indicated for each cycle and do not allow wells to sit uncovered or dry for extended periods.
- Since exact conditions may vary from assay to assay, a standard curve must be established for every run. Samples should be referred to the standard curve prepared on the same plate.
- Do not mix reagents from different batches, or other reagents and strips. Remainders should not be mixed with contents of freshly opened vials.
- Each time the kit is used, fresh dilutions of standard, sample, tracer, streptavidin-peroxidase and buffers should be made.
- Caps and vials are not interchangeable. Caps should be replaced on the corresponding vials.
- To avoid cross-contaminations, change pipette tips between reagent additions of each standard, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent.
- The waste disposal should be performed according to your laboratory regulations.

Technical support

Do not hesitate to contact our technical support team at support@hycultbiotech.com for inquiries and technical support regarding the human LBP ELISA.

Hycult Biotech, Frontstraat 2a, 5405 PB Uden, the Netherlands

T: +31 (0)413 251 335, F: +31 (0)413 248 353

FOR REFERENCE USE ONLY

12. QUALITY CONTROL

The Certificate of Analysis included in this kit is lot-specific and is to be used to verify results obtained by your laboratory. The absorption values provided on the Certificate of Analysis are to be used as a guideline only. The results obtained by your laboratory may differ.

This assay is designed to eliminate interference by soluble receptors, binding proteins, and other factors present in biological samples. Until all factors have been tested in the Hycult Biotech immunoassay, the possibility of interference cannot be excluded.

For optimal performance of this kit, it is advised to work according to good laboratory practice.

13. PERFORMANCE CHARACTERISTICS

Matrix influence in different types of plasma

Three different types of plasma (citrate, heparin and EDTA) have been tested concurrently with serum to determine the matrix influence of anticoagulants on the results. Samples of six different donors have been tested.

Sample types (n=6)	LBP µg/ml (min-max)	CV %
Citrate plasma	13.1 (8.6-25,0)	7.4
Heparin plasma	15.4 (9.8-27.9)	5.5
EDTA	11.2 (5.3-28.1)	2.8
Serum	11.9 (4.3-27.3)	6.7

Table 4

Precision and reproducibility

The intra-assay precision and reproducibility was determined with four plasma samples that were tested in duplicate.

Plasma sample (n=4)	LBP µg/ml (min-max)	CV %
S1	5.7 (5.6-5.9)	2.9
S2	7.2 (7.23-7.24)	0.1
S3	8.8 (8.7-9.0)	2.1
S4	10.4 (10.1-10.6)	3.7

Table 5

To determine the inter-assay variation, four identical plasma samples were tested on three plates by two different operators on two separate days.

Plasma sample (n=4)	LBP µg/ml (min-max)	CV %
S1	5.9 (5.8-5.9)	1.4
S2	7.3 (7.2-7.4)	1.6
S3	8.6 (8.2-8.9)	4.1
S4	11.0 (10.4-12.2)	9.2

Table 6

To determine batch-to-batch variation, four different internally validated plasma samples have been applied in plates of ten different batches and used as an internal control.

Plasma sample (n=4)	LBP µg/ml (min-max)	CV %
S1	6.7 (6.0-7.5)	7.5
S2	8.0 (7.1-9.3)	7.8
S3	9.4 (8.2-10.9)	9.7
S4	10.9 (9.6-12.2)	9.7

Table 7

FOR REFERENCE USE ONLY

14. TROUBLESHOOTING

Warranty claims and complaints in respect of deficiencies must be logged before expiry date of the product. A written complaint containing lot number of the product and experimental data shall be sent to support@hycultbiotech.com

Suggestions summarized below in Table 8 can be used as guideline in case of unexpected assay results.

Low absorbance	High absorbance	Poor duplicates	All wells positive	All wells negative	Possible cause
•	•		•	•	Kit materials or reagents are contaminated or expired
•					Incorrect reagents used
•		•	•		Lyophilized reagents are not properly reconstituted
•	•	•	•	•	Incorrect dilutions or pipetting errors
•		•			Improper plastics used for preparation of standard and/or samples
•	•				Improper incubation times or temperature
		•			Especially in case of 37°C incubation: plates are not incubated uniformly
•					Assay performed before reagents were adapted to room temperature
•	•	•	•	•	Procedure not followed correctly
				•	Omission of a reagent or a step
		•			Poor mixing of samples
	•		•		Low purity of water
	•	•			Strips were kept dry for too long during/after washing
	•	•	•		Inefficient washing
	•	•			Cross-contamination from other samples or positive control
		•	•		TMB solution is not clear or colorless
•	•				Wrong filter in the micro titer reader
	•	•			Air bubbles
		•			Imprecise sealing of the plate after use
•					Wrong storage conditions
•					Lamp in microplate reader is not functioning optimally

Table 8

FOR REFERENCE USE ONLY

15. REFERENCES

1. Labéta, M et al; Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. J Exp Med 2000, *191*: 1807
2. Blais, D et al; LBP and CD14 secreted in tears by the lacrimal glands modulate the LPS response of corneal epithelial cells. Invest Ophthalmol Vis Sci 2005, *46*: 4235
3. Lepper, P et al; Association of Lipopolysaccharide-Binding Protein and Coronary Artery Disease in Men. JACC 2007, *50*: 25
4. Redd, A et al; Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. PNAS 2009, *106*: 6718
5. Tsukamoto, H et al; Lipopolysaccharide-binding protein-mediated Toll-like receptor 4 dimerization enables rapid signal transduction against lipopolysaccharide stimulation on membrane-associated CD14-expressing cells. Int Immunol 2010, *22:* 271
6. Vikatmaa, P et al; Chlamydial lipopolysaccharide (cLPS) is present in atherosclerotic and aneurysmal arterial wall—cLPS levels depend on disease manifestation. Cardiovasc Pathol 2010, *19:* 48
7. Garate, I et al; Origin and consequences of brain Toll-like receptor 4 pathway stimulation in an experimental model of depression. J of Neuroinflam 2011, *8:* 151
8. Weg, van de A et al; Lipopolysaccharide levels are elevated in dengue virus infected patients and correlate with disease severity. J Clin Virol 2012, *53:* 38
9. Serrano, M et al; Serum lipopolysaccharide-binding protein as a marker of atherosclerosis. Atherosclerosis 2013, *230:* 223
10. López, M et al; Inflammatory markers related to microbial translocation among HIV-infected pregnant women: a risk factor of preterm delivery. J Infect Dis 2016, *213; 343*

FOR REFERENCE USE ONLY